Palatin Technologies (PTN) Stock Price, News & Analysis

Company Overview

Palatin Technologies, Inc. (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization. Its pipeline has historically included multiple candidate programs at various stages of development, and the company has sought to progress those programs through clinical trials while evaluating potential collaborations to broaden development resources and market access.

Palatin operates in the United States and engages with the broader biopharma ecosystem to advance its products. Publicly traded on the NYSE American exchange, the company has worked to leverage scientific expertise and external partnerships to move assets forward. I do not have fully verifiable, up-to-date details on current executive leadership or recent corporate milestones; readers should consult the company’s filings and official releases for the latest leadership, pipeline and strategic information.

Key Stats

• Today's Range: $7.58 to $8.20
• 50-Day Range: $7.68 to $14.88
• 52-Week Range: $5.00 to $31.00
• Volume: 5,846 shs
• Average Volume: 20,137 shs
• Market Capitalization: $13.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.00
• Consensus Rating: Buy

Palatin Technologies Stock Analysis - MarketRank™

Palatin Technologies scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Palatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Palatin Technologies has a consensus price target of $55.00, representing about 614.3% upside from its current price of $7.70.

Amount of Analyst Coverage

Palatin Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Palatin Technologies has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PTN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palatin Technologies does not currently pay a dividend.

Dividend Growth

Palatin Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for PTN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Palatin Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.10% of the stock of Palatin Technologies is held by insiders.

Percentage Held by Institutions

11.50% of the stock of Palatin Technologies is held by institutions.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 8/01/2026
• Next Earnings (Estimated): 9/02/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:PTN
• CIK: 911216
• Web: N/A
• Phone: (609) 495-2200
• Fax: 609-495-2202
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Palatin Technologies: $55.00
• High Price Target: $60.00
• Low Price Target: $50.00
• Potential Upside/Downside: +614.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.31 million
• Net Margins: N/A
• Pretax Margin: -48.50%
• Return on Equity: -141.40%
• Return on Assets: -58.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.04
• Quick Ratio: 5.04

Sales & Book Value

• Annual Sales: $4.49 million
• Price / Sales: 3.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.95 per share
• Price / Book: 1.29

Miscellaneous

• Outstanding Shares: 1,780,000
• Free Float: 1,653,000
• Market Cap: $13.71 million
• Optionable: N/A
• Beta: 0.63